Category: Right to Try
-
100+ Joined Our Virtual Community Session Recently, Where we Shared Critical Infrastructure Advancements
On December 16th, the National Psychedelics Association (the NPA) convened a well-attended virtual briefing over Zoom, bringing together facilitators, service center operators, training providers, and allied professionals from across Oregon, Colorado, and even beyond. The session was structured as a working update rather than a formal presentation, walking the community through six big benefits we offer, including…
-
Fighting for Psilocybin Access: Inside the Right-to-Try and Rescheduling Effort
As co-counsel in the federal psilocybin rescheduling case, Kathryn Tucker has witnessed firsthand the challenges, and opportunities in reforming outdated drug policy. In this conversation with Psychedelics Today, she shares the inside story of our legal strategy, the role of the Right to Try Act, and what rescheduling could mean for patients, providers, and the…
-
Right to Try (RTT) Laws: A Battle with Multiple Fronts
We have been leading efforts to open access to the investigational psychedelic drug psilocybin for therapeutic use for patients with life threatening illness through state and federal Right to Try (RTT) laws.[2] RTT laws recognize that these patients do not have the time to await the slow process of new drug approval to be completed…
-
Update re AIMS et al. v. DEA: DEA Doubles Down in Denying Dying Patients Access to Psilocybin
In January 2021, Dr. Sunil Aggarwal, a respected palliative care physician and founder of the Advanced Integrative Medical Science (“AIMS”) Institute in Seattle, sought authorization from the DEA to obtain psilocybin for therapeutic use with his dying cancer patients. Psilocybin is an investigational drug shown to be remarkably effective in relieving debilitating anxiety and depression…
-
At DEA’s Door: The Battle to Open Access to Psilocybin Therapy for Peace and Comfort at the End of Life
On Mother’s Day 2022, my client Erinn Baldeschwiler, a young mother of two with Stage IV terminal cancer travelled from Seattle to Washington D.C. instead of spending the day with her children, even thought it was likely her last Mother’s Day given the inexorable advance of her illness. Accompanied by her palliative care nurse, Erinn…
-
Efforts to Open Access to Psilocybin for Therapeutic Use for Those with Life Threatening Illness Continue
Long-time patient rights advocate Kathryn Tucker, then Special Counsel at Emerge Law Group, now Special Advocacy Advisor at the National Psychedelics Association submitted a Freedom of Information Act (“FOIA“) request to the Drug Enforcement Administration (“DEA“) on March 31, 2022 on behalf of the Seattle area palliative care clinician Dr. Sunil Aggarwal of the Advanced…
-
Four Organizations Dedicated to Disability and Patient Rights Join in the Fight for Terminally Ill Californians with Physical Disabilities
Our advocacy on behalf of Californians with terminal illnesses involving progressive loss of physical ability has been joined by a group of four organizations who provide support to and advocate on behalf of people with terminal illnesses and disabilities. The case was filed in August of 2021, and is discussed HERE. California’s End of Life…
-
Fighting for Terminally Ill Californians with Physical Disabilities
Our advocacy on behalf of Californians with terminal illnesses involving progressive loss of physical ability continues. The case was filed in August of 2021, and is discussed HERE. California’s End of Life Options Act discriminates against these disabled patients. The law allows mentally competent terminally ill adults to obtain medication that can be ingested to…
-
Ninth Circuit ducks merits in nation’s first legal challenge to allow access to psilocybin in end-of-life care under “Right-To-Try” laws
Bipartisan Congressional support for allowing terminal patients to seek relief from anxiety and depression in alignment with ongoing international research on the effectiveness of psilocybin in mental health care Statement The Ninth Circuit’s opinion today, January 31, 2022, finding that the agency action in this matter was not final – “the DEA’s response letter was…
